Skip to main content

Foley Mark J

No open-market purchases or sales filed in the past year.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Foley Mark J as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

GKOS GLAUKOS Corp

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 28, 2025 (view filing)Feb 262 daysFoley Mark JDirectorSSale−20.7K$120.72−$2.50M−27.6%54.2K after
Feb 26, 2024 (view filing)Feb 233 daysFoley Mark JDirectorSSale−4.56K$92.87−$423.5K−12.1%33.2K after

RVNC Revance Therapeutics, Inc.

President & CEO7 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 8, 2024 (view filing)Mar 62 daysFoley Mark JCEOPPurchase+30.0K$6.98+$209.4K+3.0%1.02M after
Aug 4, 2023 (view filing)Aug 31 dayFoley Mark JCEOSSale−26.3K$22.57−$593.1K−3.0%840.4K after10b5-1
Jul 5, 2023 (view filing)Jul 32 daysFoley Mark JCEOSSale−26.3K$24.94−$655.4K−2.9%866.7K after10b5-1
Jun 13, 2023 (view filing)Jun 94 daysFoley Mark JCEOSSale−31.3K$30.72−$960.9K−3.4%891.9K after10b5-1
May 16, 2023 (view filing)May 151 dayFoley Mark JCEOSSale−70.4K$34.55−$2.43M−7.1%923.2K after
Mar 9, 2023 (view filing)Mar 9Same dayFoley Mark JCEOSSale−70.4K$31.59−$2.22M−7.9%823.4K after
Nov 29, 2021 (view filing)Nov 29Same dayFoley Mark JCEOPPurchase+40.0K$12.90+$516.0K+56.4%110.9K after